Ameritas Investment Partners Inc. Has $2 Million Stake in Repligen Corporation $RGEN

Ameritas Investment Partners Inc. increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 11.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,105 shares of the biotechnology company’s stock after acquiring an additional 1,653 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Repligen were worth $2,003,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Twin Tree Management LP acquired a new stake in Repligen during the 1st quarter valued at $29,000. Hantz Financial Services Inc. raised its position in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the period. Center for Financial Planning Inc. raised its position in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares during the period. AlphaQuest LLC acquired a new stake in shares of Repligen during the 2nd quarter worth about $104,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Repligen during the 1st quarter worth about $132,000. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Repligen stock opened at $171.76 on Wednesday. The firm has a market cap of $9.67 billion, a PE ratio of 8,592.30, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The stock’s fifty day moving average price is $146.77 and its two-hundred day moving average price is $130.95. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The company’s revenue was up 21.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. As a group, research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of research reports. Barclays upped their price target on shares of Repligen from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Evercore ISI upped their target price on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of Repligen in a report on Wednesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Insider Activity

In related news, COO James Bylund sold 2,191 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Anthony Hunt sold 20,000 shares of the stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the sale, the director owned 80,743 shares in the company, valued at $12,483,675.23. The trade was a 19.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 49,382 shares of company stock valued at $7,676,802 in the last ninety days. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.